We describe the functional analysis of a novel retroviral vector, SF91m3, which was designed for improved expression of the in vivo selectable marker, multidrug resistance 1 gene (MDR1), in hematopoietic cells. SF91m3 combines several promising features. The vector backbone lacks viral coding sequences and AUG-start codons 5Ј of the MDR1 cDNA. A point mutation of a cryptic splice acceptor of the MDR1 cDNA increases the probability of transferring an intact provirus. The titer of a PG13 packaging cell clone containing a single proviral integration is high (Ͼ2 × 10 6 particles/ml from frozen stocks of serum-free vector harvests). Human hematopoietic cells transduced with SF91m3 reliably express MDR1 before and after passage through NOD/SCID mice,
Introduction
Transduction of hematopoietic cells with genes mediating resistance to cytotoxic agents has two goals: to increase the therapeutic index of anticancer chemotherapy and to allow selection of transduced hematopoietic cells in vivo. The human multidrug resistance 1 gene (MDR1) is of particular interest, because it encodes a membrane-located efflux pump that prevents intracellular accumulation of a large variety of clinically important drugs, such as anthracyclines, vinca alkaloids, taxanes, and podophyllotoxines. [1] [2] [3] [4] However, clinical studies conducted with retroviral vectors expressing MDR1 have been compromised by low gene transfer efficiency and/or insufficient expression of MDR1 in hematopoietic cells. [5] [6] [7] [8] [9] [10] Several technical and biological problems contribute to the difficulty of developing MDR1 gene therapy. To ensure polyclonal repopulation with chemoresistant cells, a large number of primitive hematopoietic cells have to be transduced. Transgene expression must be clearly above background levels that result from the activity of the cellular alleles in primitive hematopoietic cells. 11, 12 Moreover, the large cDNA of 3.9 kb gives rise to aberrant splice variants that perturb processing of vector RNA, thus generating defective proviral genomes and internally deleted, frame-shifted mRNAs in addition to the predicted full-length form. [13] [14] [15] [16] Finally, transduction of hematopoietic cells with MDR1 retroviruses at high copy numbers may give rise to a myeloproliferative syndrome. 17 Here, we describe the functional analysis of a novel retroviral vector (SF91m3) that is partially splice-corrected, has a high titer and allows efficient gene transfer with strong expression of MDR1 from limited transgene insertions in human hematopoietic cells. This vector combines four interesting features ( Figure 1 ): (a) a long terminal repeat (LTR) containing the enhancer/promoter region of murine spleen focus-forming virus (SFFVp) for efficient initiation of transcription in hematopoietic cells; 18 (b) destruction of repressor sequences that overlap with the primer binding site of conventional murine retroviruses; 18, 19 (c) a leader sequence that is devoid of viral coding sequences, contains an artificial intron in the 5Ј untranslated region, and largely eliminates aberrant reading frames for initiation of translation; 20 and (d) a silent point mutation in the cryptic splice acceptor at nucleotide +2319 of the MDR1 coding region. 13, 15 In the present study, SF91m3 is compared with a 21 In comparison with SF91m3, SF1m does not contain the modifications improving post-transcriptional processing of vector RNA (features c and d in Figure 1 ). The investigation is performed in a relevant cell system: primary human hematopoietic cells harvested from mobilized peripheral blood. Transduced cells were analyzed before and after xenotransplantation in immunodeficient NOD/SCID mice.
Results
SF91m3: Cloning of plasmid and characterization of packaging cells Plasmid pSF91m3 encoding the new MDR1 retrovirus, SF91m3, was obtained by site-directed mutagenesis of the cryptic splice acceptor at position +2319 of the MDR1 cDNA and insertion of the mutagenized cDNA into the SF91 retroviral vector. 20 The differences between SF91m3 and its precursor, SF1m, affect post-transcriptional processing of the vector RNA, whereas cis-acting elements required for initiation of transcription are identical ( Figure 1 ).
Clonal PG13 packaging cells producing SF91m3 retrovirus were established by infection from amphotropic producer cells (MOI Ͻ 1) and subsequent sorting of single cells expressing MDR1, as defined by staining with the monoclonal antibody UIC2. Forty-five clones were screened for release of high titers of SF91m3 retrovirus by supernatant transduction of HT1080 cells and subsequent quantification of MDR1-expressing cells using the Rh123 efflux assay (Figure 2a ). Two clones (RS4 and RS52) with titers Ͼ10 6 per milliliter cell culture supernatant were expanded to primary seed banks (20 vials of 1 × 10 6 cells). Southern blot analysis revealed the presence of a single integrated provirus in both cells of RS4 and RS52 (data not shown). RS4 was subsequently expanded to a master cell bank (100 vials of 1 × 10 6 cells) and used for production of defined batches of cell-free supernatants in two tray cell-factories. 22 Serum-free supernatants were harvested from these cultures and stored at −70°C. Titers of thawed aliquots were in the range of 1-3 × 10 6 infectious particles per ml (Figure 2b ). Samples of these supernatants were used for further experiments. Supernatants of SF1m were also produced from cloned PG13 cells containing a single proviral integration and had a similar titer. 22 Gene transfer in primary human hematopoietic cells PG13 cells produce replication-incompetent murine Ctype retroviruses pseudotyped with the envelope protein of the gibbon ape leukemia virus (GALV). 23 GALVpseudotyped retroviruses were previously shown to allow efficient transduction of human and primate hematopoietic cells, including primitive NOD/SCID-repopulating cells, provided that self-renewal divisions of hematopoietic cells occur and virus-cell interactions are supported using recombinant fibronectin and/or centrifugation. [24] [25] [26] [27] [28] For the present study, three experiments were performed with CD34
+ cells from mobilized peripheral blood, each in a side-by-side comparison of SF1m and SF91m3. The MOI was comparable (approximately 1.8-2.9 infectious particles per cell) according to previous titration of supernatants on HT1080 cells.
Detection of MDR1 expression in hematopoietic cells by flow cytometry: The Hoechst-efflux assay reveals differences in expression levels in favor of the modified vector, SF91m3
The fluorochromes rhodamine 123 (Rh123) and Hoechst 33342 are substrates for the efflux pump encoded by MDR1. The Rh123 efflux assay was performed with an efflux time of 1 h, thus also detecting cells with relatively weak expression of MDR1. In contrast, no time was allowed for dye efflux after staining with Hoechst 33342. 29 In this protocol, cells expressing no or only low levels of MDR1 show stronger fluorescence, whereas cells with high expression of efflux pumps may efficiently extrude the dye during staining.
Both assays provided a satisfactory resolution, with a clear separation of a dull population that occurred at increased frequency after transduction of cells with either MDR1 retrovirus ( Figures 3 and 4) . However, these two 
Increased resistance to cancer drugs in cells transduced with SF91m3
To address whether superior expression of MDR1 resulted in improved drug resistance, hematopoietic cells were plated in colony assays containing no drug (control for cloning efficiency) or increasing concentrations of colchicine (COL), a substrate of the efflux pump encoded by MDR1. This is a very stringent assay to determine the chemoprotective effect of transgenic MDR1. 11, 18 While no differences were observed between the two vectors and mock-transduced cells with respect to cloning efficiency and differentiation of colony-forming cells in the absence of COL, chemoresistance in cells transduced with SF91m3 was substantially stronger. Upon transduction with either vector, a significant proportion of colonies survived when colchicine was present in a concentration of up to 24 ng/ml, equivalent to approximately 7 × IC 50 . However, only cells transduced with SF91m3 survived exposure to COL in a dose of up to 48 ng/ml ( Figure 5 ). Although colony size was generally reduced at this drug dose, differentiation of colony-forming cells was still observed (Figure 6 ). Table 1 ).
Hematopoietic cells transduced with SF91m3 engraft in NOD/SCID mice and express MDR1 with increased probability To examine whether more primitive hematopoietic cells were transduced with SF91m3 or SF1m and retained their engraftment potential, cells were xenografted in immunodeficient NOD/SCID mice. Two experiments were performed. In the first experiment the MOI of SF1m and SF91m3 was comparable, whereas in the second experiment the MOI was about 50% lower for cells transduced with SF91m3. Bone marrow cells were harvested 6 weeks after xenotransplantation. Gene marking of human SCID repopulating cells (SRCs) with MDR1 retroviruses was determined by real-time PCR, and MDR1 expression was monitored using the Rh123 efflux assay with a gate on human CD45 + cells (Table 2) . Engraftment with human cells occurred at a frequency of 19-49%. In bone marrow samples containing human SRCs transduced with either SF91m3 or SF1m, populations of Rh123 dull cells with a high side scatter, indicative of granulocytes, were detected 6 weeks after transduction (Figure 7 ). This showed that expression of the transgene was maintained after myeloid differentiation. According to real-time PCR, SRCs were transduced at a comparable frequency in experiment one (3% for SF91m3 and 5.5% for SF1m), whereas in experiment two marking with SF1m was superior (48.7% versus 12.8% for SF91m3). Accordingly, the frequency of human Rh123 dull cells was comparable in experiment one (range 1.5-3.7% for SF1m and 1.8-5.1% for SF91m3), but relatively higher for SF1m in experiment two (range 14.1-19.3% versus 8.4-10.7% for SF91m3).
Interestingly, when normalizing expression (frequency of Rh123 dull cells) for gene transfer efficiency (frequency of gene-marked cells), cells transduced with SF91m3 reproducibly showed a superior penetrance of the transgenic phenotype. Both experiments taken together, 39.9 ± 15% of SRCs marked with SF1m expressed MDR1, as opposed to 93.2 ± 27.7% for SF91m3. This difference was highly significant according to a two population t test (P Ͻ 0.001). The fact that the ratio of expression and marking was even beyond 100% in samples from mice Nos 4 and 7 of experiment one may be explained by the variability of the assays used (see standard deviations of the real-time PCR in Table 2 ). As the Rh123 efflux assay does not introduce a bias in favor of SF91m3 (Table 1) , the increased frequency of cells expressing MDR1 following transduction with SF91m3 is likely to reflect the impact of the mutation of the cryptic splice acceptor at +2319 of the MDR1 cDNA, thus leading to an increased probability of particles containing genomic RNA for an intact provirus.
Discussion
The side-by-side comparison of SF91m3 with its predecessor, SF1m, reveals that the modifications introduced in SF91m3 for improving post-transcriptional processing of vector RNA (Figure 1 ) result in a superior fidelity of transferring an intact vector to SRCs (Table 2) , and also in elevated expression in vitro, as assessed by the Hoechst 33342 efflux assay and determination of drug resistance (Figures 4 and 5 , and Table 1 ). This was demonstrated under clinically relevant experimental conditions, using serum-free, high-titer vector preparations produced from a cloned, PG13-based packaging cell line, and hematopoietic cells harvested from mobilized peripheral blood of healthy donors.
The superior performance of SF91m3 compared with the parental vector, SF1m, can be attributed to improved post-transcriptional processing in both retroviral packaging cells and hematopoietic target cells. The optimization of the 5Ј untranslated region 20 and the mutation of the cryptic splice acceptor 13, 15 presumably co-operate for increased export and/or prolonged half-life of RNA con- Gene Therapy taining an unspliced MDR1 transcription unit, which can then be utilized for efficient translation of the efflux pump. We did not mutate the major cryptic splice donor of the MDR1 cDNA, which has been described by Sorrentino and co-workers, 15 as we observed decreased rather than increased expression when our vectors contained this mutation; the molecular mechanisms underlying this observation remain to be addressed. 30 SF91m3 meets stringent safety criteria, because a residual fragment of the viral gag gene and aberrant reading frames for initiation of translation have been removed. 20 Thus, SF91m3 also represents an interesting basis for combined expression of a second gene along with MDR1, encoding either another drug resistance gene, 15 ,31 a suicide gene, 32 a cell surface marker, 21 or a nonselectable therapeutic gene. 33 An unresolved issue is that transduction with another MDR1 retrovirus has been associated with a myeloproliferative disorder in mice, although prove of causality is still missing. 17 Recent clinical trials, [5] [6] [7] [8] [9] [10] experiments with nonhuman primates, 34 and our own mouse model (CB et al, submitted for publication) so far did not reveal a similar syndrome. Further work may elucidate the impact of gene copy numbers or other properties of the vectors or transduction conditions used, and thus help to define the therapeutic window of and appropriate vectors for MDR1 expression in human hematopoietic cells.
Figure 6 Differentiation of colony-forming cells transduced with SF91m3 in the presence of high doses (up to 48 ng/ml) of colchicine (COL
Taken together, the data shown here indicate that SF91m3 mediates strong expression of MDR1 from lim- ited transgene insertions, without profound interference with the potential for differentiation or repopulation of human hematopoietic cells. Beyond a potential impact for MDR1 gene transfer in carefully controlled clinical trials, the present report also demonstrates that improving posttranscriptional processing of retroviral vectors plays an important role for elevating transgene expression in primary human hematopoietic cells.
Materials and methods

Cloning of pSF91m3
Plasmid pSF91m3 for the novel MDR1 retrovirus, SF91m3, was obtained by site-directed mutagenesis of the cryptic splice acceptor sequence located at position +2319 of the MDR1 cDNA, using oligonucleotides MUT/ MDR1/SA1+ (5Ј-CATTTTCCTTCAAGGTTTCACATTT GGC-3Ј) and MUT/MDR1/SA1-(5Ј-GCCAAATGT GAAACCTTGAAGGAAAAATG-3Ј), and the QuikChange Site-Directed Mutagenesis Kit (Stratagene, Heidelberg, Germany), according to the manufacturer's instructions. The DNA template was plasmid pKS+ containing the MDR1 cDNA derived from pSF1m between cloning sites Not1 and BamHI. 21 Presence of the splice acceptor mutation was verified by sequencing. The cDNA was then excised using Not1 and BamHI and inserted into pSF91 opened with the same enzymes. 20 Establishment of packaging cells and vector preparation Plasmid pSF91m3 was transfected into GP+envAM12 packaging cells using superfect reagent (Qiagen, Hilden, Germany). Cell-free supernatants of transfected cells were used retrovirally to transduce PG13 cells with a multiplicity of infection (MOI) Ͻ1. Transduced PG13 cells were sorted using a FACSVantage instrument (Becton Dickinson, Heidelberg, Germany) on the basis of MDR1 (P-gp) expression, as detected with the monoclonal antibody UIC2 (P-gp (MDR)-PE, Immunotech, Krefeld, Germany). Sorted cells were clonally expanded. Clones were screened for release of infectious SF91m3 retroviral vectors by supernatant transduction of HT1080 cells and determining gene transfer rates using the Rh123 efflux assay. High-titer clones RS4 were further expanded and grown to primary seed cell banks or master cell banks as indicated in Results.
Vector preparations for transduction of CD34 + cells were harvested from confluent layers of PG13 clone RS4. For harvest of supernatants, the growth medium of PG13 cells was shifted from serum-containing to serum-free medium (X-vivo 10; BioWhittacker, Verviers, Belgium), as described. 22 Cell culture supernatants were harvested 8-16 h after medium exchange, filtered (0.45 m filter; Gelman Sciences, Dreieich, Germany) and kept frozen in aliquots at −70°C. Samples of defined vector batches were titrated on predefined numbers of HT1080 target cells. The proportion of Rh123 dull cells was determined after 2 days using the Rh123 efflux assay and used for calculation of vector titers.
Selection and transduction of CD34
+ cells The MACS CD34 Multisort Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) was used to purify CD34 + human hematopoietic cells from samples of mobilized peripheral blood following treatment of healthy donors with G-CSF. Cell donation was approved by the internal review board. The resulting purity of CD34 + cells was in the range of 96-99%. Before retroviral transduction, cells were stimulated at a density of 1 × 10 6 /ml for 16-24 h in X-vivo 10 + 2 mm l-glutamine supplemented with Flt3 ligand (100 ng/ml), stem cell factor (50 ng/ml), thrombopoietin (20 ng/ml), IL-3 (20 ng/ml) and IL-6 (10 ng/ml) (Pepro Tech, Rocky Hill, NJ, USA). Cells were transferred to dishes coated with recombinant fibronectin fragment CH-296 (20 g/cm 2 ) (TaKaRa Biomedicals, Shiga, Japan) and serum-free supernatants (MOI 1.8-2.9) were added three times within 48 h. After addition of supernatant, cells were centrifuged for 1.5 h at 1100 g and 32°C.
NOD/SCID transplantations NOD/SCID mice were kept in isolator cages under pathogen-free conditions in the animal facility of the German Cancer Research Center. Five to 24 h before transplantation, 5-to 10-week-old female mice were conditioned by sublethal irradiation (3 Gy). Human cells were injected via the tail vein. Treatment of transplanted mice with human IL-3, human G-CSF and antiasialo GM1 was administered as described. 28 Mice were killed 6 weeks after transplantation for harvesting of bone marrow cells from femures and tibiae.
Flow cytometry
The Rh123 efflux assay was performed as described, 18 using 100 ng Rh123/ml for labeling. HT1080 and human hematopoietic cells were analyzed 24-48 h after transduction. Human cells harvested from NOD/SCID mice (see below) were identified using antihuman CD45 phycoerythrin antibody (PharMingen, Hamburg, Germany). Gate criteria were adjusted according to isotype controls. Engraftment with human cells was determined by simultaneous staining with antihuman CD45 phycoerythrin and antimouse CD45 fluorescein isothiocyanate (Sigma, Deisenhofen, Germany). Dead cells were excluded by uptake of propidium iodide (Sigma).
Cells (minimum of 10 000 events) were analyzed on a FACSCalibur instrument (Becton Dickinson). Statistics were calculated using CellQuest software (Becton Dickinson).
The Hoechst efflux assay was performed as follows: 24 h after transduction, human hematopoietic cells were stained with Hoechst 33342 (5 g/ml) (Sigma) for 1 h at 37°C in the dark, at a density of 1 × 10 6 cells/ml in DMEM supplemented with 2% FCS and 1 mm Hepes. As a control, another sample of cells was stained with Hoechst 33342 in the presence of the Pgp-inhibitor, verapamil (10 m). After staining, cells were kept on ice until analysis, to prevent further Hoechst 33342 efflux. Cells (minimum of 10 000 events) were analyzed on a dual laser fluorescence activated cellsorter (FACSVantage; Becton Dickinson).
Hoechst 33342 was excited at 350 nm. To separate the emission wavelength, a 640 nm pass dichromatic mirror was used. Hoechst 33342 fluorescence was measured using a 424 nm and 44 nm BP (Hoechst blue) and a 660 nm LP optical filter (Hoechst red). Hoechst blue and Hoechst red fluorescence are shown on a linear scale. PIpositive cells were detected on the far right of Hoechst red and were excluded. PI staining did not effect the Hoechst 33342 staining profile. 29 
Colony assay
Twenty-four hours after transduction, cells were plated in semisolid media (Stem Cell Technologies, Vancouver, Canada), as described. 11 To select for MDR1-expressing cells, colchicine (COL; Sigma) was added in increasing concentrations, as indicated in Results. After 12 to 14 days of culture in a humidified incubator at 5% CO 2 and 37°C, colonies were scored microscopically. Only colonies comprising at least 50 vital appearing cells were counted.
Gene Therapy
Real-time quantitative PCR DNA of cells harvested from chimeric NOD/SCID bone marrow was purified using the QIAamp DNA Blood Mini Kit (Qiagen), and RNA was digested with 30 U RNAse A (Sigma). Triplicates of 5 l of each preparation served as templates in duplex PCRs using the ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems, Weiterstadt, Germany). Reaction A2 uses primers mdrallf (5Ј CAGGTGTGCTCGGAGCCA 3Ј) and mdr-allr (5Ј ACAGTGGTCCAGCTCCTGGAG 3Ј) to amplify a 108 bp fragment of the MDR1 cDNA (located +3231 to +3339). Product A2 was detected by the FAM-labeled TaqMan probe mdr-allp (5Ј CCATCAAGCAGCACTTTCCC TGCCA 3Ј). Reaction A2 was performed as duplex PCR simultaneously to quantify transgenic MDR1 and an endogenous human allele, the erythropoietin receptor (EpoR) gene using the primers hepo-f (CTGCT GCCAGCTTTGAGTACACTA), hepo-r (GAGATGCCA GAGTCAGATACCACAA) and the VIC-labeled TaqMan probe hepo-p (ACCCCAGCTCCCAGCTCTTGCGT). For each reaction, the cycle number generating the first fluorescent signal above a threshold was determined. The difference between the threshold cycles of reaction one and reaction two in a duplex PCR was used to quantify the percentage of MDR1-transduced human cells with reference to a standard curve over five logs as described. 28 This standard curve was obtained by amplifying template DNA prepared from different cell mixtures containing defined numbers of vector-transduced human HT1080 cells sorted into vector-negative HT1080 cells.
